Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study

Basit Öğe Kaydı
dc.authorscopusid14219156500
dc.authorscopusid15756259700
dc.authorscopusid8842895600
dc.authorscopusid6507569757
dc.authorscopusid58856288500
dc.authorscopusid23061033300
dc.authorscopusid6603070081
dc.contributor.authorAkpınar S.
dc.contributor.authorTekgunduz E.
dc.contributor.authorErkurt M.A.
dc.contributor.authorEsen R.
dc.contributor.authorYılmaz M.
dc.contributor.authorKarakus V.
dc.contributor.authorVural F.
dc.date.accessioned2024-08-04T20:02:25Z
dc.date.available2024-08-04T20:02:25Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study aimed to define distribution of different TMA forms in adult Turkish patients who were referred for therapeutic plasma exchange (TPE) for a presumptive diagnosis of TMA. Patients with serum ADAMTS13 activity <5% were diagnosed as acquired thrombotic thrombocytopenic purpura (aTTP). Patients presenting with ADAMTS13 activity 6–10 % / normal renal function and patients with ADAMTS13 activity >10 %, normal renal function and no secondary TMA were treated as unclassified TMA. The study included a total of 97 patients (female: 60; male: 30) with a median age of 48 (18?74). Detailed evaluation at 1 month after hospital admission revealed aTTP, secondary TMA, infection/complement-associated hemolytic uremic syndrome and unclassified TMA in 32 (33 %), 33 (34 %), 26 (27 %) and 6 (6%) patients respectively. As subclassification of various TMAs will dictate specific therapy, proper diagnosis in a timely manner is of utmost clinical significance. © 2021 Elsevier Ltden_US
dc.description.sponsorshipAlexion Pharmaceuticals: 100064en_US
dc.description.sponsorshipThe present study was designed as an investigator initiated trial (IIT) and sponsored by Alexion Pharmaceuticals (Tracking number: 100064)en_US
dc.identifier.doi10.1016/j.transci.2021.103312
dc.identifier.issn1473-0502
dc.identifier.scopus2-s2.0-85119255512en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103312
dc.identifier.urihttps://hdl.handle.net/11616/91673
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHematopoietic cell transplantationen_US
dc.subjectHemolytic uremic syndromeen_US
dc.subjectThrombotic microangiopathyen_US
dc.subjectThrombotic thrombocytopenic purpuraen_US
dc.titleProspective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu